01 — At a Glance
A Conglomerate Swallowing Its Own Profit Margins
- 52-Week High / Low₹1,502 / ₹945
- Q3 FY26 Revenue₹3,811 Cr
- Q3 FY26 PAT₹213 Cr
- Q3 FY26 EPS (₹)13.60
- Annualised EPS (Q3×4)₹54.40
- Book Value₹463
- Price to Book2.14x
- Dividend Yield0.92%
- Debt / Equity0.30x
- FY26 Full-Year EPS (TTM)₹42.47
The Real Story: DCM Shriram delivered its biggest quarterly topline in five years (₹3,811 Cr, +13% YoY). But bottom-line profit tumbled 5% YoY despite that revenue boom. How? Seven different businesses are doing exactly seven different things — some on fire, some struggling, some being acquired, some getting demerged. The P/E of 23.4x is juicy for a company earning 11.4% ROCE and growing at 8–9%. Meanwhile, management is busy restructuring the whole empire. Grab popcorn.
02 — Introduction
A Textbook Conglomerate Discount in Action
DCM Shriram is what happens when a 126-year-old family business refuses to pick a lane. Sugar. Chemicals. Vinyl (PVC). Fertiliser. Seeds. Building systems. And now they’re throwing in salt works and demerging consumer-facing verticals for good measure.
This isn’t a “story stock.” It’s a business laboratory. Some experiments work fantastically (Fenesta building systems is scaling brilliantly). Some are bleeding cash as we speak (Epichlorohydrin plant just commissioned, currently unprofitable). Some are being lobbied hard to the government (PVC tariffs, anyone?). And some are so mature they’re basically cash cows with zero growth (sugar, distilleries).
The company’s 9M FY26 revenue hit ₹10,345 crore, up 12% YoY. PBDIT rose 24% YoY to ₹1,294 crore. But here’s the thing: profit growth is stuck at -18% over three years. The market is clearly pricing in both the promise (new chemical projects ramping) and the pain (cyclical downturns, capex absorption). A P/E of 23.4x isn’t cheap. It’s not expensive either. It’s “show me the upside” territory.
Concall from January 2026 revealed management’s “Great Realignment” thesis: global supply chains are breaking, tariffs are weaponized, India is resilient. Good. Now can they prove it to shareholders without blowing up three segments in the process?
The Setup: Seven segments. Three are scaling with real ROIC. Two are cyclical nightmares. One is barely profitable. One (salt) just got acquired. Welcome to the Conglomerate Discount, live edition.
03 — Business Model: The Diversification Gamble
Why Putting All Your Eggs in Seven Baskets Is Actually a Strategy
DCM Shriram operates four distinct clusters: Chemicals & Vinyl (~32% of FY25 revenue), Sugar & Ethanol (~27%), Agri-Inputs (~20%), and Building Systems (~8%). The rest is fertiliser, bioseed, and stuff nobody talks about at parties.
Chemicals (Chlor-Alkali): DCM is India’s #2 caustic soda producer with 2,749 TPD capacity across Kota and Bharuch. They make chlorine, hydrogen peroxide, epichlorohydrin, and a dozen other substances that industrial India needs but nobody celebrates. The Bharuch facility is a single-location beast — 2,225 TPD caustic alone. Captive 383-MW power plants at both locations. Cost advantage = MOAT. Current problem? Epichlorohydrin (ECH) plant just commissioned October 2025 is currently loss-making. Management expects it “near breakeven within 12 months of acquisition.” Comedy gold.
Sugar: Four integrated complexes at Ajbapur, Hariawan, Loni, and Rupapur with 42,400 TCD crushing. Three distilleries (560 KLD). Seasonal revenue, cyclical margins, and right now — stuck fighting rising sugarcane costs. Next season outlook depends entirely on what the government does with MSP, exports, and ethanol blending mandates. Zero control. Maximum drama.
Fenesta Building Systems: The growth star. 413 dealers, 265 cities, uPVC windows and facades. Q3 revenue +28% YoY. Margin guidance reset to ~14% “normalized” EBITDA (down from prior 18–19% because they’re investing in scale and backward integration). New aluminium extrusion plant commissioning Q1 FY27. This is the only segment where management sounds actually excited.
Shriram Farm Solutions (SFS): Hybrid seeds, specialty nutrients, crop protection. Revenue +7% YoY in Q3. Margins got crushed because wheat prices collapsed in Kharif. They oversold wheat seed (113k MT sold vs 125-130k MT target), and excess inventory had to be dumped in mandi below cost. Next harvest decides if this is a real franchise or a seasonal dice roll.
Everything else (urea, bioseed, cement, fuel pumps) generates revenue but is basically on autopilot.
The diversification gamble: when one segment dies, three others keep the lights on. But the cost? Impossible for markets to value fairly. Hence: conglomerate discount.
04 — Financials Overview
Q3 FY26: The Quarterly Numbers
Result type: Quarterly Results | Q3 FY26 EPS: ₹13.60 | Annualised EPS (Q3×4): ₹54.40 | 9M FY26 EPS: ₹31.43
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 3,811 | 3,367 | 3,272 | +13.2% | +16.5% |
| PBDIT / EBITDA | 560 | 537 | 408 | +4.3% | +37.3% |
| EBITDA Margin % | 14.7% | 16% | 12.5% | -130 bps | +220 bps |
| PAT | 213 | 224 | 159 | -5.28% | +33.96% |
| EPS (₹) | 13.60 | 14.35 | 10.13 | -5.23% | +34.1% |
What the Numbers Are Really Saying: Revenue exploded 13% YoY. EBITDA crawled up just 4%. Net profit fell 5%. This is margin compression in real time. Why? Q3 FY25 had an extra ₹36 crore one-off (labour code benefit reversal in the sugar segment). Strip that, and Q3 FY26 profit growth is actually flat to slightly positive. The real story: high commodity costs (sugar, chemicals) are eating into margins. Capex investments in new plants (ECH, extrusion) are absorbing cash. The P/E annualized from Q3 = ₹54.40 × current stock price ₹994 = 18.3x, but FY26 TTM EPS of ₹42.47 gives a P/E of 23.4x. The market is pricing in normalisation risk.
05 — Valuation: Fair Value Range
What’s This Corporate Jigsaw Puzzle Actually Worth?
Join 10,000+ investors who read this every week.
